Trodelvy benefits people with advanced hormone-positive metastatic breast cancer
Full article:

The study TROPiCS-2 showed that the drug Trodelvy (sacituzumab govitecan) improved progression-free survival when compared to chemotherapy in people with advanced metastatic ER/PR-positive, HER2-negative breast cancer who have few other treatment options. This drug does not yet have FDA approval for use in the hormone-positive setting. (Posted 1/18/23)

Update: On 02/03/2023 the FDA approved Trodelvy for patients with locally advanced or metastatic  breast cancer who have received hormonal therapy and at least two other types of treatment in the metastatic setting.

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following studies look at treatment for people with metastatic ER-positive breast cancer.  

Other clinical trials for people with breast cancer can be found here.


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.